Challenges and opportunities of pharmacogenetics in drug development.
作者： Ruth March
关键词: Translational science 、 Biotechnology 、 Drug development 、 Pharmacogenomics 、 Pharmaceutical industry 、 Variety (cybernetics) 、 Pharmacogenetics 、 Engineering ethics 、 Drug response 、 Medicine
摘要: Drugs fail the regulatory process for a variety of reasons, including issues with pharmacokinetics, safety and efficacy. One most exciting questions in drug development today is how far science pharmacogenetics, study genetics response, can be used to address fundamental that pharmaceutical industry facing. In particular, question it possible use this emerging deliver right treatment, patient, at dose, time both challenge opportunity using pharmacogenetics development. This review will these several real-life examples.
sci-hub.se 参考文章(34)
I Zineh, T Gerhard, C L Aquilante, A L Beitelshees, B N Beasley, A G Hartzema, Availability of pharmacogenomics-based prescribing information in drug package inserts for currently approved drugs. Pharmacogenomics Journal. ,vol. 4, pp. 354- 358 ,(2004) , 10.1038/SJ.TPJ.6500284
Ruth March, Kevin Cheeseman, Michael Doherty, Pharmacogenetics--legal, ethical and regulatory considerations. Pharmacogenomics. ,vol. 2, pp. 317- 327 ,(2001) , 10.1517/14622416.2.4.317
Jason Lazarou, Bruce H. Pomeranz, Paul N. Corey, Incidence of Adverse Drug Reactions in Hospitalized Patients: A Meta-analysis of Prospective Studies JAMA. ,vol. 279, pp. 1200- 1205 ,(1998) , 10.1001/JAMA.279.15.1200
L KNUDSEN, Global gene mining and the pharmaceutical industry Toxicology and Applied Pharmacology. ,vol. 207, pp. 679- 683 ,(2005) , 10.1016/J.TAAP.2004.11.031
Federico Cappuzzo, Fred R. Hirsch, Elisa Rossi, Stefania Bartolini, Giovanni L. Ceresoli, Lynne Bemis, Jerry Haney, Samir Witta, Kathleen Danenberg, Irene Domenichini, Vienna Ludovini, Elisabetta Magrini, Vanesa Gregorc, Claudio Doglioni, Angelo Sidoni, Maurizio Tonato, Wilbur A. Franklin, Lucio Crino, Paul A. Bunn, Marileila Varella-Garcia, Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer Journal of the National Cancer Institute. ,vol. 97, pp. 643- 655 ,(2005) , 10.1093/JNCI/DJI112
Munir Pirmohamed, Sally James, Shaun Meakin, Chris Green, Andrew K Scott, Thomas J Walley, Keith Farrar, B Kevin Park, Alasdair M Breckenridge, Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients BMJ. ,vol. 329, pp. 15- 19 ,(2004) , 10.1136/BMJ.329.7456.15
G SPEAKE, B HOLLOWAY, G COSTELLO, Recent developments related to the EGFR as a target for cancer chemotherapy Current Opinion in Pharmacology. ,vol. 5, pp. 343- 349 ,(2005) , 10.1016/J.COPH.2005.02.007
David H. Johnson, Gefitinib (Iressa) trials in non-small cell lung cancer Lung Cancer. ,vol. 41, pp. 23- 28 ,(2003) , 10.1016/S0169-5002(03)00136-3
Catia Marzolini, Rommel G Tirona, Richard B Kim, Pharmacogenomics of the OATP and OAT families Pharmacogenomics. ,vol. 5, pp. 273- 282 ,(2004) , 10.1517/PHGS.5.3.273.29831
DC Anderson, , B Gomez-Mancilla, BB Spear, DM Barnes, K Cheeseman, PM Shaw, J Friedman, A McCarthy, C Brazell, SC Ray, D McHale, L Hashimoto, R Sandbrink, ML Watson, RA Salerno, N Cohen, CE Lister, Elements of informed consent for pharmacogenetic research; perspective of the pharmacogenetics working group Pharmacogenomics Journal. ,vol. 2, pp. 284- 292 ,(2002) , 10.1038/SJ.TPJ.6500131